PT1397357E - Formas polimórficas do cloridrato de 1-¿4-(5-cianoindol-3- il)butil]-4-(2-carbamoil-benzofuran-5-il)-piperazina - Google Patents
Formas polimórficas do cloridrato de 1-¿4-(5-cianoindol-3- il)butil]-4-(2-carbamoil-benzofuran-5-il)-piperazina Download PDFInfo
- Publication number
- PT1397357E PT1397357E PT02754627T PT02754627T PT1397357E PT 1397357 E PT1397357 E PT 1397357E PT 02754627 T PT02754627 T PT 02754627T PT 02754627 T PT02754627 T PT 02754627T PT 1397357 E PT1397357 E PT 1397357E
- Authority
- PT
- Portugal
- Prior art keywords
- disorders
- cyanoindol
- butyl
- piperazine
- benzofuran
- Prior art date
Links
- RPZBRGFNBNQSOP-UHFFFAOYSA-N vilazodone hydrochloride Chemical compound Cl.C1=C(C#N)C=C2C(CCCCN3CCN(CC3)C=3C=C4C=C(OC4=CC=3)C(=O)N)=CNC2=C1 RPZBRGFNBNQSOP-UHFFFAOYSA-N 0.000 title abstract 2
- 230000004048 modification Effects 0.000 abstract 2
- 238000012986 modification Methods 0.000 abstract 2
- SGEGOXDYSFKCPT-UHFFFAOYSA-N vilazodone Chemical compound C1=C(C#N)C=C2C(CCCCN3CCN(CC3)C=3C=C4C=C(OC4=CC=3)C(=O)N)=CNC2=C1 SGEGOXDYSFKCPT-UHFFFAOYSA-N 0.000 abstract 2
- 201000000736 Amenorrhea Diseases 0.000 abstract 1
- 206010001928 Amenorrhoea Diseases 0.000 abstract 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 208000020925 Bipolar disease Diseases 0.000 abstract 1
- 206010012289 Dementia Diseases 0.000 abstract 1
- 208000020401 Depressive disease Diseases 0.000 abstract 1
- 208000030814 Eating disease Diseases 0.000 abstract 1
- 208000019454 Feeding and Eating disease Diseases 0.000 abstract 1
- 208000001640 Fibromyalgia Diseases 0.000 abstract 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 abstract 1
- 206010058359 Hypogonadism Diseases 0.000 abstract 1
- 206010026749 Mania Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 206010036618 Premenstrual syndrome Diseases 0.000 abstract 1
- 201000001880 Sexual dysfunction Diseases 0.000 abstract 1
- 231100000540 amenorrhea Toxicity 0.000 abstract 1
- 206010008118 cerebral infarction Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 235000014632 disordered eating Nutrition 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000006651 lactation Effects 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 208000020016 psychiatric disease Diseases 0.000 abstract 1
- 231100000872 sexual dysfunction Toxicity 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
- 208000011117 substance-related disease Diseases 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Reproductive Health (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Gynecology & Obstetrics (AREA)
- Vascular Medicine (AREA)
- Anesthesiology (AREA)
- Urology & Nephrology (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Nutrition Science (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Pregnancy & Childbirth (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Child & Adolescent Psychology (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01113647 | 2001-06-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT1397357E true PT1397357E (pt) | 2009-11-03 |
Family
ID=8177643
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT02754627T PT1397357E (pt) | 2001-06-19 | 2002-06-05 | Formas polimórficas do cloridrato de 1-¿4-(5-cianoindol-3- il)butil]-4-(2-carbamoil-benzofuran-5-il)-piperazina |
Country Status (30)
| Country | Link |
|---|---|
| US (15) | US7381726B2 (pt) |
| EP (1) | EP1397357B9 (pt) |
| JP (3) | JP4624667B2 (pt) |
| KR (1) | KR20040012922A (pt) |
| CN (2) | CN101139345B (pt) |
| AR (1) | AR034595A1 (pt) |
| AT (1) | ATE437871T1 (pt) |
| AU (1) | AU2002320822B2 (pt) |
| BR (1) | BR0210495A (pt) |
| CA (16) | CA2782628A1 (pt) |
| CY (1) | CY1109447T1 (pt) |
| CZ (2) | CZ305220B6 (pt) |
| DE (1) | DE60233133D1 (pt) |
| DK (1) | DK1397357T3 (pt) |
| EC (1) | ECSP044943A (pt) |
| EE (1) | EE05454B1 (pt) |
| ES (1) | ES2330314T3 (pt) |
| HK (2) | HK1066003A1 (pt) |
| HU (1) | HU229601B1 (pt) |
| IL (2) | IL159426A0 (pt) |
| MX (1) | MXPA03011723A (pt) |
| MY (1) | MY151087A (pt) |
| NZ (1) | NZ530642A (pt) |
| PL (1) | PL208708B1 (pt) |
| PT (1) | PT1397357E (pt) |
| RU (1) | RU2303598C2 (pt) |
| SK (2) | SK288162B6 (pt) |
| UA (1) | UA76758C2 (pt) |
| WO (1) | WO2002102794A2 (pt) |
| ZA (1) | ZA200400329B (pt) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA76758C2 (uk) | 2001-06-19 | 2006-09-15 | Мерк Патент Гмбх | Поліморфні форми гідрохлориду 1-'4-(5-ціаноіндол-3-іл)бутил-4-(2-карбамоїлбензофуран-5-іл)піперазину |
| DE10259244A1 (de) * | 2002-12-17 | 2004-07-01 | Merck Patent Gmbh | N-(Indolethyl-)cycloamin-Verbindungen |
| DE10326939A1 (de) * | 2003-06-16 | 2005-01-05 | Merck Patent Gmbh | Indol-Derivate |
| DE10326940A1 (de) * | 2003-06-16 | 2005-01-05 | Merck Patent Gmbh | Indol-Derivate |
| WO2012131706A1 (en) * | 2011-03-20 | 2012-10-04 | Cadila Healthcare Limited | Amorphous form of vilazodone hydrochloride and process for its preparation |
| CN102219783B (zh) * | 2011-05-05 | 2013-07-03 | 天津市汉康医药生物技术有限公司 | 盐酸维拉佐酮及其组合物 |
| US9505744B2 (en) | 2011-11-23 | 2016-11-29 | Assia Chemical Industries Ltd. | Solid state forms of vilazodone and vilazodone hydrochloride |
| EP2791131A1 (en) | 2011-12-12 | 2014-10-22 | Ranbaxy Laboratories Limited | Amorphous vilazodone hydrochloride, a process for its preparation and pharmaceutical compositions thereof |
| US9969721B2 (en) | 2012-04-12 | 2018-05-15 | Alembic Pharmaceuticals Limited | Process for the preparation of vilazodone hydrochloride and its amorphous form |
| EP2838894A1 (en) * | 2012-04-16 | 2015-02-25 | Ranbaxy Laboratories Limited | Process for the preparation of crystalline vilazodone hydrochloride |
| WO2013164794A1 (en) | 2012-05-04 | 2013-11-07 | Ranbaxy Laboratories Limited | Crystalline forms of vilazodone hydrochloride |
| US20150126525A1 (en) | 2012-05-11 | 2015-05-07 | Dr. Reddy's Laboratories Limited | Crystalline forms of vilazodone hydrochloride and vilazodone free base |
| WO2013175361A1 (en) | 2012-05-24 | 2013-11-28 | Ranbaxy Laboratories Limited | Process for the preparation of vilazodone hydrochloride |
| CN102702180A (zh) * | 2012-05-25 | 2012-10-03 | 吉林三善恩科技开发有限公司 | 一种维拉佐酮有机药物共晶及其制备方法 |
| US8835635B2 (en) * | 2012-06-05 | 2014-09-16 | Symed Labs Limited | Amorphous form of vilazodone hydrochloride substantially free of crystalline forms |
| WO2013182946A2 (en) | 2012-06-06 | 2013-12-12 | Ranbaxy Laboratories Limited | Process for the preparation of vilazodone hydrochloride |
| US9382233B2 (en) | 2012-06-13 | 2016-07-05 | Apotex Inc. | Forms of vilazodone and processes for the preparation thereof |
| WO2014028473A1 (en) | 2012-08-13 | 2014-02-20 | Assia Chemical Industries Ltd. | New salts of vilazodone and solid state forms thereof |
| WO2014049609A2 (en) * | 2012-09-26 | 2014-04-03 | Cadila Healthcare Limited | Novel salts of vilazodone |
| WO2014049612A2 (en) * | 2012-09-27 | 2014-04-03 | Msn Laboratories Limited | Processes and polymorphs of 5-[4-[4-(5-cyano-1h-indol-3-yl) butyl]-1-piperazinyl]-2-benzofuran carboxamide and its salts |
| WO2014064715A2 (en) | 2012-10-22 | 2014-05-01 | Cadila Healthcare Limited | Amorphous form of vilazodone hydrochloride and process for preparing thereof |
| CN103772367B (zh) * | 2012-10-24 | 2016-05-25 | 杭州和泽医药科技有限公司 | 盐酸维拉佐酮v晶型的制备方法及其应用 |
| CN103772368B (zh) * | 2012-10-24 | 2016-08-03 | 杭州和泽医药科技有限公司 | 盐酸维拉佐酮iv晶型的制备方法及其应用 |
| WO2014087428A1 (en) * | 2012-12-07 | 2014-06-12 | Glenmark Pharmaceuticals Limited; Glenmark Generics Limited | Process for preparation of vilazodone and intermediates thereof |
| CN102977083A (zh) * | 2012-12-17 | 2013-03-20 | 南京海纳医药科技有限公司 | 1-[4-(5-氰基吲哚-3-基)丁基]-4-(2-氨甲酰-苯并呋喃-5-基)-哌嗪盐酸盐的新晶型xⅶ及其制备方法 |
| WO2014178013A1 (en) | 2013-04-30 | 2014-11-06 | Ranbaxy Laboratories Limited | Vilazodone impurities, process for their preparation, and their use as reference standards |
| IN2013MU02001A (pt) | 2013-06-12 | 2015-05-29 | Lupin Ltd | |
| EP2824104A1 (en) | 2013-07-12 | 2015-01-14 | Sandoz AG | Process for the preparation of form III of Vilazodone hydrochloride |
| WO2015019256A1 (en) | 2013-08-06 | 2015-02-12 | Ranbaxy Laboratories Limited | Pharmaceutical composition of vilazodone and processes of preparation thereof |
| WO2015019237A1 (en) | 2013-08-06 | 2015-02-12 | Ranbaxy Laboratories Limited | Pharmaceutical composition of vilazodone |
| WO2015037010A1 (en) * | 2013-09-13 | 2015-03-19 | Symed Labs Limited | Preparation of vilazodone hydrochloride crystalline form iv |
| CN104610238A (zh) * | 2013-11-01 | 2015-05-13 | 北京英科博雅科技有限公司 | 一种维拉佐酮盐酸盐iii晶型新的制备方法 |
| ITMI20131839A1 (it) * | 2013-11-06 | 2015-05-07 | Dipharma Francis Srl | Co-cristallo di un farmaco antidepressivo |
| WO2015102019A2 (en) * | 2013-12-30 | 2015-07-09 | Msn Laboratories Private Limited | Process for the preparation of polymorphs of 5-[4-[4-(5-cyano-1h-indol-3-yl)butyl]-1-piperazinyl]-2-benzofuran carboxamide hydrochloride |
| CN105017233A (zh) * | 2014-04-23 | 2015-11-04 | 天津药物研究院 | 一种盐酸维拉佐酮晶体、其制备方法、药物组合物和用途 |
| CN105820157B (zh) * | 2015-01-09 | 2021-05-25 | 石药集团中奇制药技术（石家庄）有限公司 | 一种盐酸维拉佐酮晶型及其制备方法 |
| CN106518854A (zh) * | 2016-09-21 | 2017-03-22 | 北京万全德众医药生物技术有限公司 | 一种盐酸维拉佐酮晶型ⅳ的制备方法 |
| TR201702103A2 (tr) | 2017-02-13 | 2018-08-27 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Vilazodon hi̇droklorürün tablet formlari |
| TR201702104A2 (tr) | 2017-02-13 | 2018-08-27 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Vi̇lazodon hi̇droklorür farmasöti̇k bi̇leşi̇mleri̇ |
| CN107098889A (zh) * | 2017-03-17 | 2017-08-29 | 北京万全德众医药生物技术有限公司 | 盐酸维拉佐酮药物晶型ⅲ的制备方法 |
| CN109503560A (zh) * | 2017-09-14 | 2019-03-22 | 北京万全德众医药生物技术有限公司 | 盐酸维拉佐酮ⅺ晶型的制备方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US532241A (en) * | 1895-01-08 | Computing-machine | ||
| US1294526A (en) * | 1917-09-21 | 1919-02-18 | Gerhard Nicolaas Vis | Manufacture of sodium carbonate and ammonium sulfate from bisulfate of soda. |
| DE4333254A1 (de) * | 1993-09-30 | 1995-04-06 | Merck Patent Gmbh | Piperidine und Piperazine |
| US5521241A (en) * | 1994-08-30 | 1996-05-28 | W. R. Grace & Co.-Conn. | Styrene copolymer-based plastisol containing glycidyl methacrylate |
| DE19514567A1 (de) * | 1995-04-20 | 1996-10-24 | Merck Patent Gmbh | Benzofurane |
| TW518218B (en) * | 1999-05-27 | 2003-01-21 | Merck Patent Gmbh | Pharmaceutical compositions comprising 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine or its physiologically acceptable salts for use in the treatment of sub-type anxiety disorders |
| CA2415876A1 (en) | 2000-07-13 | 2002-01-24 | Hydrogen Energy America Llc | Method and apparatus for controlled generation of hydrogen by dissociation of water |
| UA76758C2 (uk) * | 2001-06-19 | 2006-09-15 | Мерк Патент Гмбх | Поліморфні форми гідрохлориду 1-'4-(5-ціаноіндол-3-іл)бутил-4-(2-карбамоїлбензофуран-5-іл)піперазину |
| US7384020B2 (en) * | 2006-06-30 | 2008-06-10 | Amtek System Co., Ltd. | Supporting frame structure |
-
2002
- 2002-05-06 UA UA2004010354A patent/UA76758C2/uk unknown
- 2002-06-05 EE EEP200400019A patent/EE05454B1/xx unknown
- 2002-06-05 US US10/481,270 patent/US7381726B2/en not_active Expired - Lifetime
- 2002-06-05 CZ CZ2013-141A patent/CZ305220B6/cs not_active IP Right Cessation
- 2002-06-05 WO PCT/EP2002/006153 patent/WO2002102794A2/en active Application Filing
- 2002-06-05 CA CA2782628A patent/CA2782628A1/en not_active Abandoned
- 2002-06-05 CA CA2782521A patent/CA2782521A1/en not_active Abandoned
- 2002-06-05 BR BR0210495-4A patent/BR0210495A/pt not_active Application Discontinuation
- 2002-06-05 CA CA2782519A patent/CA2782519A1/en not_active Abandoned
- 2002-06-05 HU HU0400236A patent/HU229601B1/hu unknown
- 2002-06-05 DE DE60233133T patent/DE60233133D1/de not_active Expired - Lifetime
- 2002-06-05 JP JP2003506267A patent/JP4624667B2/ja not_active Expired - Lifetime
- 2002-06-05 CA CA2782517A patent/CA2782517A1/en not_active Abandoned
- 2002-06-05 MX MXPA03011723A patent/MXPA03011723A/es active IP Right Grant
- 2002-06-05 CA CA2782857A patent/CA2782857A1/en not_active Abandoned
- 2002-06-05 CZ CZ2004-26A patent/CZ304471B6/cs not_active IP Right Cessation
- 2002-06-05 AT AT02754627T patent/ATE437871T1/de active
- 2002-06-05 SK SK16-2004A patent/SK288162B6/sk unknown
- 2002-06-05 PT PT02754627T patent/PT1397357E/pt unknown
- 2002-06-05 CA CA2782865A patent/CA2782865A1/en not_active Abandoned
- 2002-06-05 DK DK02754627T patent/DK1397357T3/da active
- 2002-06-05 RU RU2004100824/04A patent/RU2303598C2/ru active
- 2002-06-05 CA CA2451028A patent/CA2451028C/en not_active Expired - Fee Related
- 2002-06-05 CA CA2683040A patent/CA2683040C/en not_active Expired - Fee Related
- 2002-06-05 CA CA2782862A patent/CA2782862A1/en not_active Abandoned
- 2002-06-05 CA CA2782761A patent/CA2782761A1/en not_active Abandoned
- 2002-06-05 CA CA2782615A patent/CA2782615A1/en not_active Abandoned
- 2002-06-05 CN CN2007101802298A patent/CN101139345B/zh not_active Expired - Lifetime
- 2002-06-05 EP EP02754627A patent/EP1397357B9/en not_active Expired - Lifetime
- 2002-06-05 AU AU2002320822A patent/AU2002320822B2/en not_active Expired
- 2002-06-05 ES ES02754627T patent/ES2330314T3/es not_active Expired - Lifetime
- 2002-06-05 CA CA2782515A patent/CA2782515A1/en not_active Abandoned
- 2002-06-05 CA CA2782494A patent/CA2782494A1/en not_active Abandoned
- 2002-06-05 NZ NZ530642A patent/NZ530642A/en not_active IP Right Cessation
- 2002-06-05 PL PL364576A patent/PL208708B1/pl unknown
- 2002-06-05 CA CA2782623A patent/CA2782623A1/en not_active Abandoned
- 2002-06-05 IL IL15942602A patent/IL159426A0/xx unknown
- 2002-06-05 SK SK5028-2012A patent/SK288334B6/sk unknown
- 2002-06-05 CN CNB028122267A patent/CN100384841C/zh not_active Expired - Lifetime
- 2002-06-05 CA CA2782868A patent/CA2782868A1/en not_active Abandoned
- 2002-06-05 KR KR10-2003-7016261A patent/KR20040012922A/ko not_active Application Discontinuation
- 2002-06-05 CA CA2782791A patent/CA2782791A1/en not_active Abandoned
- 2002-06-13 MY MYPI20022214 patent/MY151087A/en unknown
- 2002-06-19 AR ARP020102289A patent/AR034595A1/es not_active Application Discontinuation
-
2003
- 2003-12-17 IL IL159426A patent/IL159426A/en active IP Right Grant
-
2004
- 2004-01-15 EC EC2004004943A patent/ECSP044943A/es unknown
- 2004-01-15 ZA ZA2004/00329A patent/ZA200400329B/en unknown
- 2004-11-10 HK HK04108857A patent/HK1066003A1/xx not_active IP Right Cessation
-
2008
- 2008-04-28 US US12/110,704 patent/US7834020B2/en not_active Expired - Lifetime
- 2008-05-16 HK HK08105432.7A patent/HK1116165A1/xx not_active IP Right Cessation
-
2009
- 2009-09-25 US US12/566,835 patent/US7981894B2/en not_active Expired - Fee Related
- 2009-09-30 CY CY20091101023T patent/CY1109447T1/el unknown
-
2010
- 2010-02-08 JP JP2010025039A patent/JP5714824B2/ja not_active Expired - Lifetime
- 2010-02-08 JP JP2010025038A patent/JP5411734B2/ja not_active Expired - Lifetime
- 2010-11-12 US US12/945,260 patent/US20110183994A1/en not_active Abandoned
- 2010-11-12 US US12/945,272 patent/US8193195B2/en not_active Expired - Lifetime
-
2011
- 2011-04-12 US US13/085,117 patent/US8318744B2/en not_active Expired - Lifetime
- 2011-05-04 US US13/100,911 patent/US20110294824A1/en not_active Abandoned
- 2011-05-04 US US13/100,948 patent/US8236804B2/en not_active Expired - Lifetime
-
2012
- 2012-10-23 US US13/658,088 patent/US8927552B2/en not_active Expired - Fee Related
-
2013
- 2013-09-19 US US14/032,183 patent/US8673921B2/en not_active Expired - Lifetime
-
2014
- 2014-05-30 US US14/291,931 patent/US8921375B2/en not_active Expired - Fee Related
- 2014-11-21 US US14/549,779 patent/US9624204B2/en not_active Expired - Lifetime
-
2017
- 2017-03-09 US US15/454,642 patent/US20170182037A1/en not_active Abandoned
-
2019
- 2019-03-18 US US16/355,982 patent/US20190343831A1/en not_active Abandoned
-
2020
- 2020-12-01 US US17/108,101 patent/US20210251986A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT1397357E (pt) | Formas polimórficas do cloridrato de 1-¿4-(5-cianoindol-3- il)butil]-4-(2-carbamoil-benzofuran-5-il)-piperazina | |
| NO20061562L (no) | Anvendelse av 1- [4-(5-cyanindol-3yl)butyl ] -4-(2-karbamoylbenzofuran-5-yl)-piperazin og dets fysiologisk akseptable salter | |
| TW200503713A (en) | Novel compounds | |
| WO2006004937A3 (en) | Non-imidazole tertiary amines as histamine 3 receptor inhibitors for the treatment of cognitive and sleep disorders, obesity and other cns disorders | |
| PL370381A1 (en) | Substituted piperazines as modulators of the melanocortin receptor | |
| MXPA04004956A (es) | Antagonistas de la hormona concentradora de melanina basados en la piperidina para tratamiento de la obesidad y de trastornos del sistema nervioso central. | |
| CA2622760A1 (en) | Cyclopropyl amines as modulators of the histamine h3 receptor | |
| HK1082680A1 (en) | Compositions for preventing or treating pollenosis, allergic nephritis, atopic dermatitits, asthma or urticaria | |
| HUP0104838A3 (en) | 4-(aminomethyl)-piperidine benzamides for treating gastrointestinal disorders, process for their preparation and intermediates | |
| TNSN04088A1 (en) | 3, 4-disubstituted, 3, 5-disubstituted and 3, 4, 5-substituted piperidines and piperazines | |
| HUP0200284A2 (en) | 1-arenesulfonyl-2-aryl-pyrrolidine and piperidine derivatives for the treatment of cns disorders, process for their preparation and pharmaceutical compositions containing them | |
| PL350845A1 (en) | Compounds and methods for treatment of asthma, allergy and inflammatory disorders | |
| PL365895A1 (en) | Crystalline venlafaxine base and novel polymorphs of venlafaxine hydrochloride, processes for preparing thereof | |
| PL370746A1 (en) | Piperazine derivatives for use as ccr-3 receptor antagonists in the treatment of asthma | |
| NO20071466L (no) | 3-substituerte-5- og 6-aminoalkyl indol-2-karboksylsyreamider og relaterte analoger som inhibitorer av kaseinkinase IE | |
| NO20070878L (no) | Dimere piperidinderivater | |
| DE60216776D1 (de) | Neue piperidin-2,6-dion bisulfatsalze und deren verwendung für die behandlung stressbezogener gemütserkrankungen | |
| HK1122497A1 (en) | Indole derivatives as histamine 3 receptor inhibitors for the treatment of cognitive and sleep disorders, obesity and other cns disorders | |
| MY130725A (en) | Composition and method for treating allergic diseases | |
| PL366457A1 (en) | Method of producing n-substituted 2,6-dialkyl morpholines | |
| WO2004050647A3 (en) | Polymorphic forms of dihydrochloride salts of cetirizine and processes for preparation thereof | |
| NO20055514L (no) | Piperazinderivater og deres anvendelse ved behandling av neurologiske og psykiatriske sykdommer | |
| SI1353906T1 (en) | Process for the preparation of (3-cyano-1h-indol-7-yl)(4-(4-fluorophenethyl)piperazin-1-yl)-methanone and salts thereof | |
| TH57869B (th) | การใช้ในทางใหม่ของ 1-[4-(5-ไซยาโนอินดอล-3-อิล)บิวทิล]-4-(2-คาร์บาโมอิลเบนโซฟูแรน-5-อิล)พิเพอราซีน และเกลือของสารดังกล่าวซึ่งเป็นที่ยอมรับทางสรีรวิทยา | |
| ZA200404548B (en) | Method and compositions for treatment of central nervous system disorders |